NCT05261438

Brief Summary

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2019

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2021

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2021

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

January 22, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 2, 2022

Completed
Last Updated

March 2, 2022

Status Verified

September 1, 2019

Enrollment Period

1.7 years

First QC Date

January 22, 2022

Last Update Submit

March 1, 2022

Conditions

Non-squamous NSCLC

Outcome Measures

Primary Outcomes (2)

  • OS

    overall survival

    September 2019- september 2021

  • PFS

    progression-free survival

    September 2019- september 2021

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Advanced Metastatic Non-squamous Non-small Cell Lung Cancer

You may qualify if:

  • ，Advanced Metastatic Non-squamous NSCLC Treatment Plan is atezolizumab-bevacizumab-carboplatin-paclitaxel

You may not qualify if:

  • Patients with contraindication of chemotherapy Pregnant or breast feeding women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hunan Cancer Hospital

Changsha, Hunan, 410013, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

tissue sample and plasma DNA

Study Officials

  • Yongchang Zhang, MD

    Hunan Cancer Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
HunanPTH

Study Record Dates

First Submitted

January 22, 2022

First Posted

March 2, 2022

Study Start

September 1, 2019

Primary Completion

May 1, 2021

Study Completion

September 15, 2021

Last Updated

March 2, 2022

Record last verified: 2019-09

Locations

CN(1)